23:48 , Aug 22, 2017 |  BC Extra  |  Company News

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...
23:55 , Jul 13, 2017 |  BC Week In Review  |  Company News

Almirall lowers guidance

Almirall S.A. (Madrid:ALM) lowered its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared to 2016, and it guided to EBITDA of...
22:18 , Jul 10, 2017 |  BC Extra  |  Financial News

Almirall sags after lowering guidance

Almirall S.A. (Madrid:ALM) fell €3.21 (25%) to €9.80 on Monday after lowering its 2017 top-line and earnings guidance. The dermatology company now expects 2017 revenues and sales to fall in the low double digits compared...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Company News

GlaxoSmithKline, Almirall deal

GlaxoSmithKline granted Almirall rights to develop and commercialize Veltin Gel clindamycin/tretinoin worldwide and Altabax retapamulin in the U.S. in exchange for distribution rights to Toctino alitretinoin in Austria, the Czech Republic, Italy, the Netherlands, Poland,...
02:48 , Dec 19, 2015 |  BC Extra  |  Company News

Management tracks

Medigene AG (Xetra:MDG1) named CSO Dolores Schendel CEO, effective Feb. 1. She will replace Frank Mathias. Vice Chairman Dave Lemus will become COO on Jan. 1. Anti-parasitic company Turing Pharmaceuticals AG (Zug, Switzerland) said CEO...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Acticlate doxycycline hyclate regulatory update

Almirall’s Aqua Pharmaceuticals LLC unit said FDA approved an NDA for Acticlate doxycycline hyclate to treat several infections, including adjunctive treatment of severe acne. The company plans to begin marketing the oral tetracycline antibiotic “in...
07:00 , Aug 4, 2014 |  BioCentury  |  Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

Almirall, Aqua Pharmaceuticals, RoundTable Healthcare Partners deal

Almirall completed its acquisition of dermatology company Aqua from private equity firm RoundTable for $327.6 million in cash, plus up to $75 million in milestone payments (see BioCentury, Dec. 23, 2013). Almirall S.A. (Madrid:ALM), Barcelona,...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Company News

Aqua Pharmaceuticals, Almirall, RoundTable Healthcare Partners deal

Almirall will acquire dermatology company Aqua from private equity firm RoundTable for $327.6 million in cash, plus up to $75 million in milestone payments. Almirall said the acquisition provides it "greater therapeutic and geographic diversification"...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Aqua Pharmaceuticals, GlaxoSmithKline sales and marketing update

Aqua acquired U.S. rights to Verdeso 0.05% desonide foam from GlaxoSmithKline's Stiefel Laboratories Inc. subsidiary. The low-potency topical steroid formulated with 0.05% desonide in emollient foam delivery vehicle is approved to treat mild to moderate...